Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06538649 · ClinicalTrials.gov registry record · Early Phase 1

Effect of Statins on Crohn's Disease

A Early Phase 1 study of Crohn Disease and Crohn's Ileocolitis, sponsored by Stanford University.

Recruiting
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT06538649: Recruiting Early Phase 1 study of Crohn Disease and Crohn's Ileocolitis, sponsored by Stanford University.

NCT06538649 is a Early Phase 1 study of Crohn Disease and Crohn's Ileocolitis that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06538649, a Early Phase 1 study of Crohn Disease and Crohn's Ileocolitis, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is: * Can statins reduce the formation of strictures in participants with stricturing Crohn's disease? Researchers will compare statins to a placebo (a look-a-like substance that contains no drug) to see if statins work to prevent strictures from forming. Participants will: * Take statins or a placebo every day for 6-12 months * Visit the clinic for lab tests twice after starting either statins or placebo * Complete questionnaires about symptoms and medications * Respond to monthly check-ins (via phone call) during participation

Primary Outcome

Will be assessed at post surgery surveillance colonoscopy. Minimum score is i0 (no lesions) and maximum score is i4 (diffuse inflammation with already larger ulcers, nodules and/or narrowing), with higher scores meaning a worse outcome.

Interventions

  • OTHER Placebo
  • DRUG Rosuvastatin

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-12
Est. Completion 2028-10-31
Phase Early Phase 1
Stanford University

1,744 total trials

What NCT06538649 shows while recruiting

NCT06538649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06538649 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06538649 about?

NCT06538649 is a clinical study titled "Effect of Statins on Crohn's Disease". The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is: * Can statins reduce the formation of strictures in participants with stricturing Crohn's disease? Researchers will compare statins to a placebo...

What is the current status of trial NCT06538649?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-12-12. Estimated completion is 2028-10-31.

What conditions does trial NCT06538649 study?

This clinical trial studies the following conditions: Crohn Disease, Crohn's Ileocolitis.

What interventions are being tested in trial NCT06538649?

The interventions under investigation include: Placebo (OTHER), Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT06538649?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06538649 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06538649's enrollment target sits among peer trials

20 63rd of 71 higher than 7 of 71 other Crohn Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06538649, the US trial registry maintained by the National Library of Medicine. NCT06538649 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.